ResMed Inc. (NYSE:RMD) Director Peter C. Farrell sold 20,000 shares of ResMed stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $75.15, for a total value of $1,503,000.00. Following the completion of the sale, the director now directly owns 321,557 shares in the company, valued at approximately $24,165,008.55. The sale was disclosed in a legal filing with the SEC, which is available at this link.

ResMed Inc. (NYSE:RMD) traded down 0.05% during midday trading on Monday, hitting $75.05. 573,222 shares of the stock were exchanged. The stock has a market cap of $10.66 billion, a price-to-earnings ratio of 31.27 and a beta of 0.83. The firm’s 50-day moving average is $77.30 and its 200 day moving average is $71.87. ResMed Inc. has a 52 week low of $56.59 and a 52 week high of $79.63.

ResMed (NYSE:RMD) last posted its quarterly earnings data on Tuesday, August 1st. The medical equipment provider reported $0.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.75 by $0.02. The business had revenue of $556.69 million during the quarter, compared to analysts’ expectations of $557.68 million. ResMed had a net margin of 16.56% and a return on equity of 21.99%. The business’s revenue was up 7.3% on a year-over-year basis. During the same period last year, the firm posted $0.74 earnings per share. Equities research analysts expect that ResMed Inc. will post $3.05 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 21st. Stockholders of record on Thursday, August 17th will be issued a $0.35 dividend. The ex-dividend date of this dividend is Tuesday, August 15th. This is a boost from ResMed’s previous quarterly dividend of $0.33. This represents a $1.40 annualized dividend and a dividend yield of 1.87%. ResMed’s dividend payout ratio (DPR) is 54.77%.

TRADEMARK VIOLATION NOTICE: “ResMed Inc. (NYSE:RMD) Director Peter C. Farrell Sells 20,000 Shares” was originally published by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/08/07/resmed-inc-nysermd-director-peter-c-farrell-sells-20000-shares-2.html.

A number of equities research analysts have weighed in on the company. Zacks Investment Research raised ResMed from a “sell” rating to a “hold” rating in a report on Tuesday, June 20th. Credit Suisse Group lowered ResMed from an “outperform” rating to a “neutral” rating in a report on Wednesday, August 2nd. Bank of America Corporation lowered ResMed from a “buy” rating to a “neutral” rating in a report on Wednesday, August 2nd. Citigroup Inc. raised ResMed from a “neutral” rating to a “buy” rating in a report on Wednesday, August 2nd. Finally, Needham & Company LLC reaffirmed a “sell” rating on shares of ResMed in a report on Wednesday, August 2nd. Four analysts have rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $65.63.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. DnB Asset Management AS boosted its position in ResMed by 28.6% in the first quarter. DnB Asset Management AS now owns 13,500 shares of the medical equipment provider’s stock valued at $972,000 after buying an additional 3,000 shares during the period. Gateway Investment Advisers LLC boosted its position in ResMed by 43.8% in the first quarter. Gateway Investment Advisers LLC now owns 85,381 shares of the medical equipment provider’s stock valued at $6,145,000 after buying an additional 26,015 shares during the period. Louisiana State Employees Retirement System boosted its position in ResMed by 2.6% in the first quarter. Louisiana State Employees Retirement System now owns 35,800 shares of the medical equipment provider’s stock valued at $2,577,000 after buying an additional 900 shares during the period. American Research & Management Co. boosted its position in ResMed by 3.2% in the first quarter. American Research & Management Co. now owns 11,340 shares of the medical equipment provider’s stock valued at $816,000 after buying an additional 350 shares during the period. Finally, Fox Run Management L.L.C. boosted its position in ResMed by 19.7% in the first quarter. Fox Run Management L.L.C. now owns 7,900 shares of the medical equipment provider’s stock valued at $569,000 after buying an additional 1,300 shares during the period. Institutional investors and hedge funds own 60.68% of the company’s stock.

ResMed Company Profile

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Insider Buying and Selling by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.